

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 16, No. 9

May 12th, 2017

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association* and membership news. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- CMS, ASCO, CMA QPP resources
- AB72 takes effect July 1
- ANCO's *The State of Cancer Care* at ASCO's *Best of ASCO*
- Help elect oncologist to *AMA President-Elect*
- ASCO's diversity strategic plan

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members. The next regular *ANCO FAX News* will be published on May 26th. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; execdir@anco-online.org.

The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!

- Physician Members
- Nurses & Office Managers
- Office Staff
- Colleagues & Representatives

The Association of Northern California Oncologists (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge. The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

The *Medicare Quality Payment Program (QPP)*, established by the *Medicare Access and CHIP Reauthorization Act (MACRA)* began on January 1st. This year is a transition year meaning you can “pick your pace” when implementing QPP in your practice. CMS has posted new resources to the QPP website to help clinicians successfully participate in the first year of the QPP. The new resources focus on support for small practices and alternative payment models (APMSs). Visit qpp.cms.gov for more information. CMS is also encouraging physicians to sign up for the new CMS QPP listserv to stay up-to-date on new resources, upcoming milestones and deadlines, and CMS webinars on the QPP. To subscribe to the QPP listserv, go to qpp.cms.gov and select “Subscribe to Email Updates” at the bottom of the page.

ASCO is releasing a series of webinars to guide oncology practices to successful quality reporting:

- May 15th—Quality Payment Program: Scoring the Quality Measures
- June 19th—Quality Payment Program: Scoring for Advancing Care Information and Improvement Activities
- July 10th—Quality Payment Program: Optimizing your MIPS Score

All webinars are schedule for 1PM PT. Register at www.asco.org/macra > MACRA Webinar Series. For more information and access to ASCO's revamped QPP/MACRA toolkit, educational materials, and resources, go to www.asco.org/macra.

CMA is hosting a webinar entitled *How California Physicians Can Access Free Technical Assistance for MACRA Transition* on May 31st at

12:15PM. Register for the webinar at www.cmanet.org/events. CMA's *Center for Economic Services (CES)* has published an update to its MACRA preparation checklist entitled *MACRA: What Should I Do Now to Prepare?* available at www.cmanet.org/macra.

CMS is reviewing claims and letting practices know which clinicians need to take part in MIPS. Through May, more than 200,000 practices will get a letter from Noridian/JEMAC informing them of the participation status of each NPI for the qualifying clinicians associated with the TIN of a practice. For more information, visit www.asco.org/advocacy-policy/asco-in-action/mips-participation-status-letter-being-sent-practices-late-april?et_cid=39205413&et rid=933038345&linkid=MIPS+Participation+Status+Letters+Coming+to+Practices+Through+May. Alternatively, clinicians may now use an interactive tool at qpp.cms.gov to determine if they should participate in the MIPS track of the QPP in 2017.

CMS has announced that it is now accepting hardship exceptions from the meaningful use requirements of the EHR incentive payment program for the 2016 reporting year. Physicians who can show that demonstrating meaningful use would result in a significant hardship can apply for a one-year exception and avoid a negative payment adjustment in 2018. The deadline is July 1st. Go to www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/PaymentAdj_Hardship.html for more information and applications.

CMA, MOASC, and State Legislative & Regulatory Issues

The *California Oncology Political Action Committee* (or CalCancerPAC), formed by ANCO and MOASC, supports candidates sensitive to the needs of hematologists/oncologists and people living with cancer in California. ANCO membership dues include a contribution to CalCancerPAC.

AB72, a new law that will change the billing practices of non-participating physicians providing non-emergent care at in-network facilities, takes effect on July 1st. The law, signed in 2016, is designed to reduce unexpected medical bills when patients go to

an in-network facility but receive care from an out-of-network physician. CMA is hosting a free webinar to educate physicians about the new law on May 17th at 12:15PM. For more information and to register, visit www.cmanet.org/events.

CMA Practice Resources (CPR) is a monthly e-mail bulletin from CMA's *Center for Economic Services* that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit www.cmanet.org/cpr to subscribe. The May 2017 edition includes:

- CMS publishes short videos on getting started with MACRA
- Medi-Cal EHR incentive program reporting deadline extended
- Reminder: Failure to revalidate Medicare enrollment information could result in deactivation
- The Coding Corner: Four requirements to append modifier 59 correctly

Noridian/JEMAC, DHCS/MediCal, & Private Payers

Noridian Administrative Services is the Jurisdiction E (JE) **Medicare Administrative Contractor (MAC)**. Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews *Announcements*—MIPS: Submit Measures for the Advancing Care Information Performance Category by June 30; EHR Incentive Programs: Review 2017 Program Requirements; Open Payments Program Year 2016 Review and Dispute Period Ends May 15; Lookup Tool to Help Determine MIPS Participation Status; Requesting Appeals Redeterminations
Publications—SNF Billing Reference Booklet-Revised
- Open Public Meeting Announcement-June 1, 2017

- Non-Covered Services LCD-R16
- EoD Extras Now Available
- There is Still Time to Evaluate Our Services!
- Draft LCDs Published for Review and Comments
- Ask the Contractor Teleconference-May 18, 2017
- Office of the Inspector General Report-Stem Cell Transplantation-Revised SE1624
- QMB Indicator in the Medicare Fee-For-Service Claims Processing System-Revised CR9911
- Payment for Moderate Sedation Services Furnished with Colorectal Cancer Screening Tests CR10075
- Medicare B News JE April 2017 Now Available

Noridian/JEMAC's Electronic Data Interchange Support Services (EDISS) invites you to subscribe to its e-mail distribution list to receive current information at www.edissweb.com/cgp/news/index.html.

Forthcoming Noridian/JEMAC meetings/workshops include:

- Noridian Medicare Portal Registration and Functionality (May 17)
- Noridian Medicare Website Tour for Part B Providers (May 23)
- Mammography, Pap Test, Pelvic Exam, and Cervical Cancer with HPV Tests (May 31)

Visit med.noridianmedicare.com/web/jeb/education/training-events for more information and to register.

According to Noridian/JEMAC, their coverage edits for HCPCS code G0498 currently only covers the code when used with trabectedin and this is an error. They are currently updating their coverage edits to include additional drugs (J codes) that could be infused via pump over an extended period-of-time. A new coverage article is being prepared and will be published by *Noridian/JEMAC*. It will include several additional covered drugs, including J9000 (doxorubicin), J9181 (etoposide), J9190 (flourouracil), and J9371 (vincristine). Additional

drugs will be added as necessary. ANCO has learned that a mass adjustment has been ordered. Practices may appeal denials to be overturned.

Anthem Blue Cross has announced that effective **May 15th**, **Myriad Genetic Laboratories** will no longer be an in-network laboratory provider. A complete list of in-network participating laboratories may be obtained online at www.anthem.com/ca > Provider > Find a Doctor.

UnitedHealthcare's Network Bulletin (May 2017) is now available online at www.unitedhealthcareonline.com > Tools & Resources > News & Network Bulletin and features articles entitled New Prior Authorization and Notification App Launching on Link; and, Revisions to Evaluation and Management Policy.

UnitedHealthcare's commercial reimbursement policies will begin requiring biosimilar biological products to include a modifier that identifies the manufacturer of the specific product for dates of service on or after June 1st. Specifically, the modifier for Q5101 (filgrastim) Zarxio will be ZA (Novartis/Sandoz) and the modifier for Q5102 (infliximab) Inflectra will be ZA (Pfizer/Hospira).

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

ANCO's 2017 Hematologic Malignancies Updates

ANCO is organizing a series of *Hematologic Malignancies Updates* in 2017. The first *Update* took place on May 6th at the *Sacramento Hyatt Regency* with Mehrdad Abedi, M.D., *University of California, Davis*, Sandy Wong, M.D., *University of California, San Francisco*, and Julian Davis, M.D., *University of California, Davis*. The latest research on novel treatment modalities for hematologic malignancies, myeloma, and amyloidosis, along with case studies for these diagnoses were presented. These updates are supported by *Janssen Biotech*, *Merck*, *Pfizer Oncology*, and *Pharmacyclics*. Download the presentations at www.anco-online.org/education.html.

The State of Cancer Care: ANCO Event at ASCO's Best of ASCO 2017

ANCO's *ASCO Highlights* will not take place in 2017 in lieu of our encouragement of members to attend ASCO's *Best of ASCO* in San Francisco (west-boa.asco.org; June 16-17th). However, ANCO will host an event on June 15th entitled *The State of Cancer Care* with Margaret Tempero, M.D., and Wes Kidder, M.D., *University of California, San Francisco*, at the *San Francisco Marriott Marquis*. Download the meeting announcement/registration form at www.anco-online.org/ANCOatBOA2017.pdf.

Additional Education Meetings

May 16th
Living with Chronic Myelogenous Leukemia (CML)
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

May 16th
Engaging Multidisciplinary Clinicians in Genomic Tumor Boards
ACCC
(www.accc-cancer.org/webinars)

May 17th
Understanding the Costs of Care and Your Health Care Coverage (Part II of Life with Cancer: A Guide to Getting the Best Care)
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

May 18th
Immuno-Oncology Management Best Practices 2.0
ACCC
(www.accc-cancer.org/webinars)

May 18th
Progress in the Treatment of Multiple Myeloma
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

May 19th
The Role of Immunotherapy in the Treatment of Melanoma (Part III of Living with Advanced Skin Cancer)
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

May 22nd
Preventing Chemotherapy Induced Nausea and Vomiting
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

May 23rd*Advances in the Treatment of Lung Cancer (Part I of Living with Lung Cancer)*CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)May 24th*Cancer and the Workplace: Understanding Your Legal Protections (Part III of Life with Cancer: A Guide to Getting the Best Care)*CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)June 2nd-6th*2017 ASCO Annual Meeting*ASCO
Chicago
(am.asco.org)June 7th*Participating in Decisions about Your Care (Part IV of Life with Cancer: A Guide to Getting the Best Care)*CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)June 13th*For Caregivers: Practical Tips to Cope with Your Loved One's Lung Cancer (Part II of Living with Lung Cancer)*CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)June 14th*For Caregivers: Care Coordination for Your Loved One Living with Cancer and Other Health Problems (Part V of Life with Cancer: A Guide to Getting the Best Care)*CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)June 16-17th*Best of ASCO*ASCO
San Francisco
(boa.asco.org)June 20th*Advances in the Treatment of Metastatic Prostate Cancer (Part I of Living with Prostate Cancer)*CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)June 21st*Update on the Treatment of Bladder Cancer*CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)June 27th*For Caregivers: Coping with a Loved One's Prostate**Cancer (Part II of Living with Prostate Cancer)*CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)June 29-30th*POLST: It Starts with A Conversation*Coalition for Compassionate Care of California
Long Beach
(coalitionccc.org/training-events/polst-education/)June 30th*Medical Update on Acute Myelogenous Leukemia (AML)*CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)July 14-15th*16th Annual International Congress on the Future of Breast Cancer West*Physicians' Education Resource
San Diego(ANCO member discount code IBW17ANCO
www.gotoper.com/conferences/ibc/meetings/16th-annual-international-congress-on-the-future-of-breast-cancer)July 27-29th*18th Annual International Lung Cancer Congress*Physicians' Education Resource
Huntington Beach(ANCO member discount code ILC17ANCO
www.gotoper.com/conferences/ilc/meetings/18th-international-lung-cancer-congress)

Please contact the ANCO office for more information about these meetings.

**ASSOCIATION & MEMBERSHIP
NEWS, RESOURCES, & BENEFITS**
[Editor's Note: All ANCO members are also eligible for several tangible benefits.]

Board of Directors

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The **next regularly scheduled ANCO Board of Directors meeting is scheduled for May 24th**. Please call José Luis González, *ANCO Executive Director*, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

ANCO member Hope S. Rugo, M.D., *UC San Francisco*, will be named a *Fellow of the American Society of Clinical Oncology (FASCO) at the 2017 ASCO Annual Meeting*. The FASCO designation recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO.

ASCO has endorsed Barbara McAneny, M.D., in her campaign for *President-Elect of the American Medical Association (AMA)*. She is a medical oncologist/hematologist from New Mexico and would be the first oncologist elected to serve as *AMA President*. Dr. McAneny is an active ASCO volunteer who has served on the *ASCO Board of Directors (2005-2008)* and as a liaison to the *AMA House of Delegates (2002-2013)*. She has also long been active in the AMA, and is past *Chair* and member of the *AMA Board of Trustees*. ANCO asks all members who are also AMA members to reach out to their AMA delegates and encourage them to vote for Dr. McAneny for *President-Elect* in the June 2017 election. For more information, visit www.barbaramcaneny.com.

A current *Directory of Members* is available online at www.anco-online.org/pubs.html as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at execdir@anco-online.org with any corrections, additions, and/or deletions.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO Board believes that the *Association* and *The Permanente Medical Group (TPMG)* will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Diablo Valley Oncology & Hematology Medical Group, EPIC Care, Marin Cancer Care, Pacific Cancer Care, Palo Alto Medical Foundation, and Valley Medical Oncology Consultants* for their multi site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

*AbbVie • Agendia • Alexion Pharmaceuticals
AMGEN • ARIAD Pharmaceuticals
Astellas Oncology • AstraZeneca
Bayer Healthcare Pharmaceuticals
bioTheragnostics
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Cardinal Health Specialty Solutions
Celgene • Clovis Oncology • Daiichi Sankyo
Dendreon • Eisai • EMD Serono • Exelixis
Foundation Medicine
Genoptix Medical Laboratory
GenPath Oncology • Genentech BioOncology
Genomic Health • Gilead Sciences
Guardant Health • Helsinn Oncology
Heron Therapeutics • Incyte
Infinity Pharmaceuticals
Ipsen Biopharmaceuticals
Janssen Oncology • Jazz Pharmaceuticals
Kite Pharmaceuticals • Lilly Oncology •
Merrimack Pharmaceuticals
Medivation • Merck
nanoString • Novartis Oncology
Oncology Supply/ION • Pfizer Oncology
Pfizer US Biosimilars • Pharmacyclis
Sandoz Biopharmaceuticals • Sanofi Genzyme
Seattle Genetics • Taiho Oncology
Takeda Oncology • Tesaro • TEVA Oncology*

We especially wish to thank and welcome *Agendia, bioTheragnostics, EMD Serono, Kite Pharmaceuticals, and Pfizer US Biosimilars* as new Corporate Members for 2017. Please visit

www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

AstraZeneca informs ANCO that the *United States Food and Drug Administration* has approved Imfinzi for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

EMD Serono and **Pfizer Oncology** inform ANCO that the *United States Food and Drug Administration* has approved Bavencio for patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant platinum-containing chemotherapy.

Genentech BioOncology informs ANCO that the *United States Food and Drug Administration* has approved a revised USPI for Herceptin (dated 4/2017) that lists a new 150mg single-dose configuration, along with additional label changes to meet updated FDA guidance. The new 150mg single-dose vial configuration for Herceptin will be introduced on May 30th. All customers will be asked to transition to the 150mg single-dose vial, once available. After July 7th *Genentech* will only ship 150mg vials to distributors and will discontinue shipping the 440mg multiple-dose vial to distributors.

Merck informs ANCO that the *United States Food and Drug Administration* has approved Keytruda in combination with pemetrexed and carboplatin for the treatment of patients with previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC).

Novartis Oncology informs ANCO that the *United States Food and Drug Administration* (FDA) has approved Rydapt for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy. The drug is approved for use in combination with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients

with AML. In addition, the FDA approved the Kisqali Femara Co-Pack for the treatment of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in postmenopausal women.

Takeda Oncology informs ANCO that the *United States Food and Drug Administration* has approved Alunbrig for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

Clinical Trial News

The ASCO Research Community Forum 2017 Annual Meeting is being held on September 24-25th at ASCO. The theme of this year's meeting is advancing cancer care through research partnerships. Register today at www.asco.org/research-progress/research-community-forum/forum-annual-meeting?

UC San Francisco brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- A Phase I Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma (CC#139511). PI: Thomas Martin, MD, tom.martin@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT02332850>
- An Open-Label Dose-Escalation and Multi-Center Study to Evaluate the Safety and Pharmacokinetics of SAR650984 in Patients with Relapsed/Refractory Multiple Myeloma (CC#15959). PI: Thomas Martin, MD, tom.martin@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT02514668>
- A Phase 1b study of the safety and pharmacokinetics of Atezolizumab [MPDL3280A (anti-PD-L1 antibody)] alone or in combination with an immunomodulatory drug and/or daratumumab in patients with Multiple Myeloma (relapsed/refractory and post-autologous stem cell transplant; CC#15254). PI: Thomas Martin, MD, tom.martin@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT02431208>
- A Phase II Study of IRD (Ixazomib, Lenalidomide & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma (CC#152514). PI: Thomas Martin, MD, tom.martin@ucsf.edu; more information at

<https://clinicaltrials.com/ct2/show/NCT02253316>

- A Phase 1, Dose Escalation/Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Patients with Relapsed/Refractory Multiple Myeloma (CC#14954). PI: Jeffrey Wolf, MD, jeffrey.wolf@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT02223598>
- A Randomized Phase II Trial of Myeloablative vs Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-Cell Lymphoma (CC#CALGB51101). PI: James Rubenstein, MD, james.rubenstein@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT01511562>
- A Multicenter Phase I Dose-Finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax) in Combination With Roxorubicin HCL Liposomal (Doxil) for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma (CC#112516). PI: Ai Weiyun, MD, ai.weiyun@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT01902225>
- A Phase II Study of Intensive Consolidation and Stem Cell Mobilization Therapy with Ofatumumab, Etoposide, and High Dose ARA-C (OVA), followed by Autologous Stem Cell Transplantation in High-Risk Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (CC#112525). PI: Charalambos Andreadis, MD, charalambos.andreadis@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT01555541>
- Ph ½ Study of Intratumoral G100 With or Without Pembrolizumab Therapy in Patients With Follicular Non-Hodgkin's Lymphoma (CC#152518). PI: Ai Weiyun, MD, ai.weiyun@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT02501473>
- A Phase ½ Study of the Safety, Tolerability, and Efficacy of Epcadostat Administered in Combination With Nivolumab in Select Advanced Cancers (CC#15856). PI: Charalambos Andreadis, MD, charalambos.andreadis@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT02327078>
- A randomized double-blind phase III study of Ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large b-cell lymphoma of the activated b-cell subtype (CC#A051301). PI: Charalambos Andreadis, MD, charalambos.andreadis@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT02443077>

- A Phase I Study of Stem Cell Gene Therapy for HIV Mediated By Lentivector Transduced, Pre-Selected CD34+ Cells, A Trial of the AIDS Malignancy Consortium (OHAM; AMC097). PI: Lawrence Kaplan, MD, lawrence.kaplan@ucsf.edu

- A Phase ½, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ASN002 in Relapsed/Refractory Lymphoma and Advanced Solid Tumors (CC#152516). PI: Lawrence Kaplan, MD, lawrence.kaplan@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT02440685>

- A Phase Ib Study of Ficiatuzumab with High Dose Cytarabine in Relapsed and Refractory AML (CC#139510). PI: Charalambos Andreadis, MD, charalambos.andreadis@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT02109627>

- A Phase 1 Dose Escalation Study of DS 3032B, and Oral MDM2 Inhibitor, in Subjects with Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) in Blast Phase, or High Risk Myelodysplastic Syndrome (MDS) (CC#14956). PI: Rebecca Olin, MD, rebecca.olin@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT02319369>

- A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation (CC#15255). PI: Gabriel Mannis, MD, charalambos.andreadis@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT02074839>

- A Phase ½ Multi-Center Study Evaluating the Safety and Efficacy of KTE-C10 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL; CC#152511). PI: Aaron Logan, MD, aaron.logan@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT02348216>

- Phase 1b Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes in Previously Treated Patients or in Untreated Patients Unfit for or Who Refuse Intense Therapy (r/r ALL; CC#16254). PI: Aaron Logan, MD, aaron.logan@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT02348216>

- An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia (CC#142513). PI: Charalambos Andreadis, MD,

charalambos.andreadis@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT02282215>

- A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination with Corticosteroids versus Placebo in Combination with Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD; CC#17254). PI: Aaron Logan, MD, aaron.logan@ucsf.edu; more information at <https://clinicaltrials.com/ct2/show/NCT02959944>
- Expanded Access Protocol for Therapeutic use of ¹⁷⁷Lu-DOTA0-Tyr3-Octreotate in Patients with Inoperable, Somatostatin Receptor Positive, Midgut Carcinoid Tumors, Progressive Under Somatostatin Analogue Therapy. Contact: Bryant Chee, (415) 353-7145, bryant.chee@ucsf.edu
- Lifestyle and Outcomes after Gastro-Intestinal Cancer: A Prospective Cohort Study (LOGIC; CC#154520). Contact: Marissa Savoie, (415) 353-7683, succeedstudy@ucsf.edu
- Survivor Choices for Eating and Drinking (Succeed)—Colorectal Cancer (CC#164511). Contact: Marissa Savoie, (415) 353-7683, logicstudy@ucsf.edu
- A Phase 1, Open-Label, Dose-Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics and Clinical Effects of Orally Administered CB-5083 in Patients with Advanced Solid Tumors (CC#149511). Contact: Kathleen (Katie) Comerford, (415) 514-6674, kathleen.comerford@ucsf.edu
- A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination with FOLFIRI for Patients with Previously Treated Metastatic Colorectal Cancer (CC#159510). Contact: Armand Harb, (415) 353-7381, armand.harb@ucsf.edu.
- A Phase 1, Open-Label, Dose-Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics and Clinical Effects of Orally Administered CB-5083 in Patients with Advanced Solid Tumors (CC#149511). Contact: Kathleen (Katie) Comerford, (415) 514-6674; kathleen.comerford@ucsf.edu
- A Phase I Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer (CC#169517). Contact: Jenna Zhang, (415) 353-8337; jenna.zhang@ucsf.edu

Publications, Resources, Services, & Surveys

ASCO's landmark *Strategic Plan to Increase Racial and Ethnic Diversity in the Oncology Workforce* has

been published in the *Journal of Clinical Oncology*. Learn more about ASCO's *Diversity in Oncology Initiative* at www.asco.org/practice-guidelines/cancer-care-initiatives/diversity-oncology-initiative?et_cid=39197237&et_rid=933038345&linkid=Diversity+in+Oncology.

ASCO's *Clinical Affairs Department* is dedicated to providing services, education, and resources to support oncology practices. It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit www.asco.org/asco-in-action/asco's-clinical-affairs-department-opens-new-survey-practice-operations.

ASCO has posted an *Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-III A Resectable Non-Small Cell Lung Cancer* guideline at www.asco.org/practice-guidelines/quality-guidelines/guidelines/lung-cancer. In addition, **ASCO's *Clinical Practice Guidelines Committee (CPGC)* is conducting a survey to solicit topics for clinical practice guideline development** and/or updates or endorsements. Complete the survey at www.surveymonkey.com/s/ascoguidelinesurvey by June 30th.

ASCO's PracticeNET is a collaborative network in which practices share and receive insights to enhance their business operations and quality of care. PracticeNET is the first initiative of ASCO's *Clinical Affairs Department*. This new initiative uses existing data from your practice management system to offer customizable reports that measure practice-wide and individual performance against a national database of other PracticeNET participants. Go to www.asco.org/PracticeNET for more information.

ASCO and *Innovative Oncology Business Solutions (IOBS)* have announced a new collaboration, ASCO COME HOME—an oncology medical home program designed to transition community oncology practices from volume-based to value-based care by structuring reimbursement around the full range of services needed by patients with cancer. ASCO COME HOME will also prepare oncology practices for full implementation of the Quality Payment Program under MACRA and will be available across the country starting on

January 1st, 2017. ASCO is now recruiting practices for the fee-based 2017 ASCO COME HOME program. For more information, please visit www.asco.org/practice-guidelines/practice-support/asco-consulting-services/asco-come-home.

In 2017, practices will also be able to use the QOPI platform to meet the MIPS reporting requirement of one measure through manual reporting. While one measure is the minimum requirement to avoid the 2019 penalty, ASCO encourages all practices to report on at least four measure to become fully acquainted with the system and ensure that the CMS requirements are met. For more information, please visit www.asco.org/practice-guidelines/billing-coding-reporting/macra-quality-payment-program/macra-resources.

ACCC's 2017 Patient Assistance and Reimbursement Guide is an essential tool for cancer program staff to use in helping patients with issues related to the cost of treatment and in meeting reimbursement challenges. The *Guide* features a list of pharmaceutical and non-pharmaceutical patient assistance programs (PAPs), including directions on how to apply and links to enrollment forms. Visit www.accc-cancer.org/publications/pdf/Patient-Assistance-Guide-2017.pdf to access this resource. In addition, ACCC has developed a tool for accessing patient assistance and reimbursement programs for use on a desktop, table, or mobile device. The *Financial Advocacy Network* (FAN) app is available at acc-fan-app.org. **ASH also has a webpage (at www.hematology.org/Clinicians/Drugs/Programs/) that provides a consolidated list of resources for hematologists and patients trying to access high cost hematologic drugs.** Finally, *assistPoint* is your website for complimentary one-stop cancer Patient Assistance. You can search by generic, brand name, manufacturer, or diagnosis for the enrollment forms you need; get enrollment form PDFs for cancer drugs; get NDC numbers for all of those drugs; find the HCPCS J-code for each drug; get coding and billing guidelines for many drugs; and, learn more about the drugs you give. Go to www.assistpoint.com to learn more.

ASH is now accepting nominations for members to participate in its 7th annual Advocacy Leadership Institute taking place September 27-28th in Washington, D.C. This two-day workshop is an opportunity for ASH members who wish to learn about legislation and health policy affecting

hematology research and practice. Nominations are being accepted through June 16th. Learn more at www.hematology.org/Advocacy/ALI.aspx.

NCCN has published and/or updated their *Chemotherapy Order Templates, Clinical Practice Guidelines in Oncology, Drugs & Biologics Compendium, Guidelines for Patients, Imaging Appropriate Use Criteria, and/or Radiation Therapy Compendium* for bladder cancer (V3.2017); breast cancer (V2.2017); breast cancer screening and diagnosis (V2.2016); esophageal and esophagogastric cancer (V1.2017); gastric cancer (V1.2017); head and neck cancers (V2.2017); myeloid growth factors (V1.2017); older adult oncology (V2.2017); pancreatic adenocarcinoma (V2.2017); primary cutaneous B-cell lymphomas (V2.2017); and, uterine neoplasms (V2.2017). Go to www.nccn.org for more information. NCCN is pleased to offer pocket-sized versions of the NCCN *Clinical Practice Guidelines in Oncology* for a number of their guidelines at www.nccn.org/redirects/nicelines.asp?Type=general.

Individual Membership Dues for 2017

Third notices of membership renewal for 2015 were mailed in early April. If you have not yet done so, then please return your 2017 membership dues to ANCO now to ensure your inclusion in *The ANCO Directory of Members*. Be sure to provide ANCO with your e-mail address and the name(s) and e-mail address(es) of office and/or nurse manager contact(s). Those not renewing their membership by June 30th will be deleted from the *Directory of Members*, and will no longer be eligible for any ANCO benefits. Contact the ANCO office if you do not receive or misplaced your membership dues renewal notice.